Antibody prevalence after three or more COVID-19 vaccine doses in individuals who are immunosuppressed in the UK: a cross-sectional study from MELODY
Key Points
Key points are not available for this paper at this time.
Abstract
UK Research and Innovation, Kidney Research UK, Blood Cancer UK, Vasculitis UK and the Cystic Fibrosis Trust.
اسأل الذكاء الاصطناعي
Like
Bookmark
Share
View Full Paper
اسأل الذكاء الاصطناعي
Like
Bookmark
Share
View Full Paper
Antibody prevalence after three or more COVID-19 vaccine doses in individuals who are immunosuppressed in the UK: a cross-sectional study from MELODY | Synapse